Zenas Biopharma Inc To Discuss Phase 3 IgG4-RD Registration Trial Topline Results Transcript
Good morning, everyone. Welcome to the Zenas Biopharma conference call. (Operator Instructions) Be advised that this call is being recorded at the company's request, and a replay will be available in the investors section of the company's website following the call. I'll now turn the call over to Jennifer Fox, Chief Business Officer and Chief Financial Officer of Zenice. Jennifer, you may begin.
Thank you, operator, and thank you all for joining us to discuss the topline results of our registrational phase 3 indigo trial for obilumab for the treatment of immunoglobulin G4-related disease or IgG4RD.
Before we begin, I would like to remind you of the disclaimer outlined on slide number 2. During today's presentation, including during the question-and-answer portion of the call, we will be making certain forward-looking statements. Any statements contained in this call that relate to expectations or Predictions of future events, results, or performance are forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
